Download PDF

1. Company Snapshot

1.a. Company Description

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States.The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders.The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Show Full description

1.b. Last Insights on TCMD

Tactile Systems Technology's recent performance was driven by strong Q4 2025 earnings, which beat estimates with $0.46 per share, surpassing the Zacks Consensus Estimate of $0.44 per share. The company's revenue increased 21% year-over-year to $103.6 million, with a gross margin of 78%. The acquisition of LymphaTech expanded its lymphedema solutions portfolio and strengthened R&D capabilities. Additionally, the company repurchased $26.5 million of stock at an average price of $12.36 per share, demonstrating its commitment to shareholder value.

1.c. Company Highlights

2. Tactile Systems' Strong Q4 Performance and Future Outlook

Tactile Systems reported a robust Q4 with total revenue increasing 21% year-over-year to $103.6 million, driven by a 16% rise in lymphedema product sales to $89.5 million and a 66% surge in airway clearance product sales to $14.1 million. The company's gross margin stood at 78.2% of revenue, and operating income jumped 50% to $18.8 million. Net income also rose, with earnings per share (EPS) of $0.46, beating estimates. The company's acquisition of LymphaTech and its integration into Tactile's operations are expected to drive future growth.

Publication Date: Mar -09

📋 Highlights
  • Total Revenue Growth:: 2025 full-year revenue reached $329.5M (+12% YoY), driven by $89.5M in lymphedema sales (+16% YoY) and $14.1M in airway clearance sales (+66% YoY).
  • Margin Expansion:: Gross margins expanded 190 bps to 75.9%, with Q4 gross margin at 78.2%, and adjusted EBITDA rose 21% to $44.8M.
  • 2026 Guidance:: Projects revenue of $357M–$365M (+8–11% YoY), with adjusted EBITDA of $49M–$51M, reflecting market leadership and strategic investments.
  • LymphaTech Acquisition:: Acquired for $125M to enhance lymphatic dysfunction solutions, adding 3D digital scanning tech to improve patient monitoring and therapy access.
  • Market Position Strengthening:: Airway clearance product AffloVest grew 66% YoY, securing market leadership, while Medicare payer mix remained strong in Q4.

Revenue Growth and Profitability

The company's revenue growth was driven by its lymphedema and airway clearance businesses, with the latter experiencing a significant 66% increase in sales. The company's gross margin expansion was driven by operational efficiencies and cost management. Tactile's EBITDA margin also improved, driven by investments in sales force expansion and technology.

Outlook and Valuation

For 2026, Tactile Systems expects total revenue to grow between 8% to 11%, with adjusted EBITDA projected to range from $49 million to $51 million. The company's guidance incorporates a balanced approach, considering both headwinds and tailwinds, including the impact of a recent Medicare regulatory update. With a current P/E Ratio of 33.8 and EV/EBITDA of 15.18, the market appears to be pricing in a moderate growth trajectory. The company's ROE of 9.26% and ROIC of 7.55% indicate a relatively strong return on equity and invested capital.

Strategic Priorities and Initiatives

Tactile Systems is focused on three strategic priorities: improving access to care, expanding treatment options, and enhancing the lifetime patient value. The company's acquisition of LymphaTech is expected to strengthen its market leadership in conditions associated with lymphatic dysfunction and expand its R&D capabilities. The integration of LymphaTech's digital 3D scanning technology is expected to enhance patient experience and provide a sticky solution for patients to understand their disease.

Challenges and Opportunities

The company faces challenges, including the recent Medicare regulatory update related to prior authorization for pneumatic compression devices, which may cause a temporary short-term impact on the lymphedema market. However, Tactile Systems is well-positioned to navigate this change, with a strong sales organization and investments in technology to facilitate the prior authorization process. The company's airway clearance business is also expected to continue growing, driven by the launch of a bronchiectasis drug and increasing awareness in the market.

3. NewsRoom

Card image cap

Tactile Systems Technology (TCMD) is an Incredible Growth Stock: 3 Reasons Why

Mar -09

Source: zacks.com

Card image cap

Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

Mar -09

Source: globenewswire.com

Card image cap

Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 28.34%: Read This Before Placing a Bet

Feb -26

Source: zacks.com

Card image cap

3 Reasons Why Growth Investors Shouldn't Overlook Tactile Systems Technology (TCMD)

Feb -20

Source: zacks.com

Card image cap

Tactile Systems Technology (TCMD) Just Overtook the 50-Day Moving Average

Feb -19

Source: zacks.com

Card image cap

Why Tactile Systems Technology Stock Surged by Nearly 18% Today

Feb -19

Source: fool.com

Card image cap

Tactile Systems Technology Analysts Raise Their Forecasts After Better-Than-Expected Q4 Earnings

Feb -18

Source: benzinga.com

Card image cap

Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript

Feb -18

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.32%)

6. Segments

Lymphedema

Expected Growth: 10.3%

Growing prevalence of lymphedema, increasing adoption of innovative solutions, and rising awareness about the condition drive the market growth, with Tactile Systems Technology, Inc. at the forefront with its pioneering treatments.

Airway Clearance

Expected Growth: 10.5%

Growing prevalence of respiratory diseases, increasing adoption of non-invasive therapies, and advancements in wearable technology drive the demand for Airway Clearance devices, fueling market growth.

7. Detailed Products

Flexitouch System

A pneumatic compression device designed to treat lymphedema and other circulatory disorders

ACTitouch System

A pneumatic compression device designed to treat lymphedema and other circulatory disorders in the comfort of one's own home

Entre System

A pneumatic compression device designed to treat venous ulcers and other wounds

8. Tactile Systems Technology, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Tactile Systems Technology, Inc. is medium due to the availability of alternative technologies and products in the market.

Bargaining Power Of Customers

The bargaining power of customers for Tactile Systems Technology, Inc. is high due to the presence of large and established customers who can negotiate prices and terms.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Tactile Systems Technology, Inc. is low due to the availability of multiple suppliers and the company's ability to negotiate prices.

Threat Of New Entrants

The threat of new entrants for Tactile Systems Technology, Inc. is medium due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry for Tactile Systems Technology, Inc. is high due to the presence of several established competitors and the need to constantly innovate and improve products.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 20.64%
Debt Cost 3.95%
Equity Weight 79.36%
Equity Cost 10.07%
WACC 8.81%
Leverage 26.01%

11. Quality Control: Tactile Systems Technology, Inc. passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotricity

A-Score: 5.2/10

Value: 9.6

Growth: 5.6

Quality: 6.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Tactile Systems Technology

A-Score: 4.9/10

Value: 3.1

Growth: 7.7

Quality: 7.1

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Electromed

A-Score: 4.0/10

Value: 1.9

Growth: 8.8

Quality: 7.4

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Talis Biomedical

A-Score: 3.9/10

Value: 8.2

Growth: 4.6

Quality: 4.4

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Quipt Home Medical

A-Score: 3.8/10

Value: 8.2

Growth: 6.3

Quality: 3.8

Yield: 0.0

Momentum: 3.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Myomo

A-Score: 3.1/10

Value: 8.5

Growth: 4.7

Quality: 4.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

27.86$

Current Price

27.86$

Potential

-0.00%

Expected Cash-Flows